目的:观察2型糖尿病(type 2diabetes mellitus, T2DM)动脉粥样硬化(atherosclerosis, AS)患者血清中成纤维细胞生长因子(fibroblast growth factor, FGF)19水平,并探讨FGF19水平与氧化应激发生发展的相关性。方法:选取T2DM患者78例,以颈动脉内中膜厚度(carotid intima-media thickness, CIMT)为标准分为两组,T2DM患者(n=38)为对照组,T2DM合并AS患者(n=40)为实验组,记录所有入组患者血压、计算体质量指数(body mass index, BMI);检测血糖、血脂等相关生化指标;使用酶联吸附免疫法(ELISA)测定血清FGF19、丙二醛(malondialdehyde, MDA)、谷胱甘肽过氧化物酶(glutathione peroxidase, GSH-Px)、血红素氧合酶-1(heme oxygenase-1, HO-1)水平,生化法测定超氧化物过氧化歧化酶(superoxide peroxide dismutase, SOD)水平。观察两组之间相关指标水平差异,Pearson 相关分析血清FGF19水平与HO-1、SOD、MDA、GSH-PX、CIMT、臂-踝脉冲波速(brachial ankle pulse wave velocity, baPWV)的相关性,多元线性回归分析CIMT的影响因素。结果:与对照组相比,实验组CIMT、baPWV、HO-1、MDA均升高(P＜0.01),FGF19、SOD、GSH-Px明显降低(P＜0.01)。相关性分析结果显示:实验组样本血清FGF19水平与HO-1、MDA、CIMT、baPWV呈负相关(r=-0.668、-0.657、-0.901、-0.734,P＜0.01),与SOD、GSH-Px呈正相关(r=0.345、0.760,P＜0.01)。多元线性回归分析表明FGF19、HO-1、SOD、MDA、GSH-PX均是CIMT的可能影响因素(P＜0.05)。结论:T2DM合并AS患者血清FGF19的水平与氧化应激有一定关系,且对预测AS的发生及进展具有重要临床意义。
Objective: To investigate the relationship between serum fibroblasts growth factor (FGF) 19 level and the development of atherosclerosis (AS) in patients with type 2 diabetes mellitus (T2DM). Methods: A total of 78 T2DM patients were selected and divided into two groups based on carotid intima-media thickness (CIMT). Among them, 40 T2DM patients were control group and 38 T2DM patients with AS were experimental group. Record the blood pressure and body mass index (BMI) of all inclusive patients. Detection of related biochemical indicators such as blood sugar, blood lipids. Serum FGF19, heme oxygenase-1 (HO-1),malondialdehyde (MDA), glutathione peroxidase (GSH-Px) levels were measured by enzyme-linked adsorption immunosorbent assay (ELISA), and superoxide peroxide dismutase (SOD) level was determined by biochemical method. The differences in outcome measures between the two sets were compared. The correlations between FGF19 level and HO-1, SOD, MDA, GSH-Px, CIMT and brachial ankle pulse wave velocity (baPWV) were analyzed by Pearson correlation analysis. Multiple linear regression analysis was performed to analyze the influencing factors of FGF19. Results: Compared with the control group, CIMT, baPWV, HO-1, MDA increased in the experimental group (P＜0.01), FGF19, SOD and GSH-Px decreased significantly compared with the control group (P＜0.01). Correlation analysis showed that the serum FGF19 level of the experimental group was negatively correlated with HO-1, MDA, CIM, baPWV(r=-0.668、-0.657、-0.901、-0.734,P＜0.01) were positively correlated with SOD and GSH-px (r=0.345、0.760,P＜0.01).Multiple linear regression analysis showed that FGF19, HO-1, SOD, MDA, GSH-PX were all the possible influencing factors of CIMT (P＜0.05). Conclusion: Serum FGF19 level in T2DM patients has a certain relationship with oxidative stress, and has important clinical significance in predicting the occurrence and progression of AS.
[1] Saeedi P, Salpea P, Karuranga S, et al. Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res ClinPract, 2020, 162: 108086.
[2] Tang MJ, Su JB, Xu TL,et al. Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients[J]. Diabetol Metab Syndr, 2019, 11: 79.
[3] Henriksson E, Andersen B. FGF19 and FGF21 for the treatment of NASH-Two sides of the same coin? differential and overlapping effects of FGF19 and FGF21 from mice to human[J]. Front Endocrinol (Lausanne), 2020, 11: 601349.
[4] Zhang J, Li H, Bai N, et al. Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner[J]. J Endocrinol Invest, 2019, 42: 1019-1027.
[5] Furukawa S, Fujita T, Shimabukuro M,et al. Increased oxidative stress in obesity and its impact on metabolic syndrome[J]. J Clin Invest, 2004, 114: 1752-1761.
[6] de M Bandeira S, da Fonseca LJ, da S Guedes G,et al. Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus[J]. Int J Mol Sci, 2013, 14: 3265-3284.
[7] Chatuphonprasert W, Lao-Ong T, Jarukamjorn K. Improvement of superoxide dismutase and catalase in streptozotocin-nicotinamide-induced type 2-diabetes in mice by berberine and glibenclamide[J]. Pharm Biol, 2013, online ahead of print.
[8] Yaribeygi H, Atkin Stephen L, Sahebkar A, et al.A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress[J]. J Cell Physiol, 2019, 234: 1300-1312.
[9] Yaribeygi H, Butler Alexandra E, Barreto George E, et al. Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients[J]. J Cell Physiol, 2019, 234: 2436-2446.
[10] Yuan T, Yang T, Chen H, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis[J]. Redox Biol, 2019, 20: 247-260.
[11] Azemi Ahmad K, Mokhtar Siti S, Hou Low J, et al. Model for type 2 diabetes exhibits changes in vascular function and structure due to vascular oxidative stress and inflammation[J]. Biotech Histochem, 2021, 96: 498-506.
[12] Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23[J]. Nat Rev Drug Discov, 2016, 15(1): 51-69.
[13] Massafra V, Pellicciari R, Gioiello A, et al. Progress and challenges of selective Farnesoid X Receptor modulation[J]. Pharmacol Ther, 2018, 191: 162-177.
[14] Byun S, Jung H, Chen J, et al. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis[J]. J Biol Chem, 2019, 294: 8732-8744.
[15] Xu M, Huang Y, Xie L, et al. Diabetes and risk of arterial stiffness: a mendelian randomization analysis[J]. Diabetes, 2016, 65: 1731-1740.
